Pancreatic Cancer Research

ResearcherBrown UniversityActive in the last 2 years

Kosuke Ogawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2482-2909; OpenAlex author ID A5006227724. Sources: OpenAlex.

Their work

Papers
12
Trials
0
Grants
0
Labs led
0
Collaborators
30
Papers, trials and grants by year

2019: 3 papers · 2020: 2 papers · 2021: 3 papers · 2022: none · 2023: 2 papers · 2024: none · 2025: none · 2026: 2 papers

Papers 12

  1. Corrigendum to "Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma" [Cancer Lett. 449 (2019) … Co-author DOI 10.1016/j.canlet.2025.218118↗
  2. Corrigendum to "Prometastatic secretome trafficking via exosomes initiates pancreatic cancer pulmonary metastasis" [Cancer Lett. 481 (2020) 63-75]. Co-author DOI 10.1016/j.canlet.2025.218119↗
  3. Identification of a novel target of SETD1A histone methyltransferase and the clinical significance in pancreatic cancer. Co-author DOI 10.1111/cas.15615↗
  4. RRM1 is mediated by histone acetylation through gemcitabine resistance and contributes to invasiveness and ECM remodeling in pancreatic cancer. Co-author DOI 10.3892/ijo.2023.5499↗
  5. C646 inhibits G2/M cell cycle-related proteins and potentiates anti-tumor effects in pancreatic cancer. Co-author DOI 10.1038/s41598-021-89530-8↗
  6. Prediction of early recurrence of pancreatic ductal adenocarcinoma after resection. Co-author DOI 10.1371/journal.pone.0249885↗
  7. Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells. Co-author DOI 10.1371/journal.pone.0252917↗
  8. Prometastatic secretome trafficking via exosomes initiates pancreatic cancer pulmonary metastasis. Co-author DOI 10.1016/j.canlet.2020.02.039↗
  9. Successful conversion surgery of distal pancreatectomy with celiac axis resection (DP-CAR) with double arterial reconstruction using saphenous vein grafting fo… Co-author DOI 10.1186/s40792-020-01082-7↗
  10. Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality. Co-author DOI 10.1002/ijc.32072↗
  11. Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2019.02.006↗
  12. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway. Co-author DOI 10.1186/s13045-019-0837-z↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiroaki Ono · 7 shared papers, 2019–2023 · strength 0.86
  2. Minoru Tanabe · 7 shared papers, 2019–2023 · strength 0.86
  3. Shinji Tanaka · 6 shared papers, 2020–2023 · strength 0.78
  4. Xuewei Bai · 5 shared papers, 2019–2026 · strength 0.74
  5. Katsuya Nagaoka · 5 shared papers, 2019–2026 · strength 0.74
  6. Xiaoqun Dong · 5 shared papers, 2019–2026 · strength 0.74
  7. Jack R. Wands · 5 shared papers, 2019–2026 · strength 0.74
  8. Shuichi Watanabe · 6 shared papers, 2019–2023 · strength 0.73
  9. Daisuke Ban · 5 shared papers, 2019–2021 · strength 0.55
  10. Tomotaka Kato · 3 shared papers, 2021–2023 · strength 0.40
  11. Qiushi Lin · 3 shared papers, 2019–2026 · strength 0.38
  12. Lianxin Liu · 3 shared papers, 2019–2026 · strength 0.38
  13. Rui Kong · 3 shared papers, 2019–2026 · strength 0.38
  14. Le Li · 3 shared papers, 2019–2026 · strength 0.38
  15. Howard P. Safran · 3 shared papers, 2019–2026 · strength 0.38
  16. Yoshiki Murase · 3 shared papers, 2020–2023 · strength 0.37
  17. Toshiro Ogura · 3 shared papers, 2019–2021 · strength 0.32
  18. Daisuke Asano · 2 shared papers, 2023 · strength 0.31
  19. Min Li · 2 shared papers, 2019–2026 · strength 0.30
  20. Yongwei Wang · 1 shared paper, 2026 · strength 0.22
  21. Aya Maekawa · 2 shared papers, 2020–2021 · strength 0.22
  22. Ayano Kabashima · 1 shared paper, 2023 · strength 0.16
  23. Takeshi Ishii · 1 shared paper, 2023 · strength 0.16
  24. Yongwei Wang · 2 shared papers, 2019–2020 · strength 0.16
  25. Toshitaka Sugawara · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.